Radiopharmaceuticals and Sarcopenia
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: closed (25 January 2024) | Viewed by 563
Special Issue Editors
Interests: Body Composition, Bioelectrical Impedance Analysis, Sarcopenia, Data Analysis
Interests: Body Composition Imaging, Functional Body Imaging, Sarcopenia, Steatohepatitis
Special Issue Information
Dear Colleagues,
Sarcopenia is defined as a loss of skeletal muscle mass and function related to aging, drugs, or malignancy. It is a systemic disease that is characterized by degenerative change, inflammatory process, mitochondrial dysfunction, etc. Since sarcopenia is associated with functional impairment, disability, falls, fractures, and other consequences that reduce the quality of life and increased mortality, it presents an issue of growing concern particularly in the developing world and aging world.
This Special Issue invites research and review articles on the use of radiopharmaceuticals as a tool to study the mechanisms of sarcopenia. The mechanisms covering aging, inflammation, metabolism, nutrition, protein synthesis, drugs, and malignancy are some of the research areas that this Special Issue aims to include. The use of radiopharmaceuticals to study the anatomy, physiology or pathology of adipose tissue, skeletal muscle, and body composition is also welcome.
Dr. Kuen-Chang Hsieh
Dr. Li-Wen Lee
Dr. Hsueh-Kuan Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- aging
- cachexia
- cancer
- body composition
- chemotherapy
- sarcopenia
- sarcopenic obesity
- skeletal muscle index
- toxicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
